MedTrace Logo

Efficacy of CL22205 to Improve Menstrual Discomfort and Quality of Life

NCT06760988 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2025-03-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of CL22205 to improve menstrual discomfort and quality of life in oligomenorrheic female subjects.

Conditions

  • Menstrual Discomfort

Interventions

DIETARY_SUPPLEMENT

CL22205

Experimental Dose: 200 mg, Mode: Oral, once daily after breakfast Duration: 135 days

OTHER

Placebo

Mode: Oral, once daily after breakfast Duration: 135 days

Sponsors & Collaborators

  • Eetho Brands, Inc

    lead INDUSTRY

Principal Investigators

  • Dr. Varuni B.G · Consultant

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-02-24
Primary Completion
2025-10-05
Completion
2026-01-10

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06760988 on ClinicalTrials.gov